|
| 36315007 | Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. | Blood Adv | 2023 |
| 37553873 | Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. | Cancer Med | 2023 |
| 37645727 | Bioluminescence Assay of Lysine Deacylase Sirtuin Activity. | bioRxiv | 2023 |
| 36949155 | Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. | Leukemia | 2023 |
| 36947811 | Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions. | Blood | 2023 |
| 37213193 | Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. | JMIR Res Protoc | 2023 |
| 37300657 | Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. | Curr Treat Options Oncol | 2023 |
| 36727397 | Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. | Haematologica | 2023 |
| 34482403 | Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. | Blood | 2022 |
| 35643868 | Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. | Leukemia | 2022 |
| 35640224 | Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. | Blood Adv | 2022 |
| 35570071 | Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. | Blood Rev | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 35951346 | CSF3R and SETBP1 getting high on LSD1. | Blood | 2022 |
| 36054756 | Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. | Am J Hematol | 2022 |
| 35317837 | Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. | J Hematol Oncol | 2022 |
| 34991679 | Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. | J Hematol Oncol | 2022 |
| 34491344 | Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. | J Natl Cancer Inst | 2022 |
| 34780648 | MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis. | Blood | 2022 |
| 33412552 | Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells. | Acta Haematol | 2021 |
| 33623882 | Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. | Hemasphere | 2021 |
| 33513367 | Eradicating residual chronic myeloid leukaemia: basic research lost in translation. | Lancet Haematol | 2021 |
| 33785864 | Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. | Leukemia | 2021 |
| 33773846 | Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. | Blood Rev | 2021 |
| 33745886 | Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. | J Allergy Clin Immunol | 2021 |
| 34916286 | Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. | Proc Natl Acad Sci U S A | 2021 |
| 34873345 | Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. | Nat Med | 2021 |
| 34873347 | Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. | Nat Med | 2021 |
| 34407543 | Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. | Blood | 2021 |
| 34638347 | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. | Cancers (Basel) | 2021 |
| 34608880 | Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. | Blood Coagul Fibrinolysis | 2021 |
| 34027418 | SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. | Blood Cancer Discov | 2021 |
| 33112162 | Imatinib, cheese and migraines. | Leuk Lymphoma | 2021 |
| 33337259 | Genetic complexity of chronic myelomonocytic leukemia. | Leuk Lymphoma | 2021 |
| 33180106 | Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. | JAMA Oncol | 2021 |
| 32127639 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. | Leukemia | 2020 |
| 31980730 | Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. | Leukemia | 2020 |
| 31880950 | Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | J Clin Oncol | 2020 |
| 33106665 | Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. | Nat Med | 2020 |
| 33005329 | Pregnancy outcomes in patients treated with bosutinib. | Int J Hematol Oncol | 2020 |
| 32835547 | Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Leuk Lymphoma | 2020 |
| 32974613 | Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. | Blood Cancer Discov | 2020 |
| 32886902 | Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32999432 | Imatinib is not a potent anti-SARS-CoV-2 drug. | Leukemia | 2020 |
| 32908250 | Declaration of Bcr-Abl1 independence. | Leukemia | 2020 |
| 32672489 | No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group. | Leuk Lymphoma | 2020 |
| 33022644 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32409689 | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. | Leukemia | 2020 |
| 32563283 | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. | Lancet Haematol | 2020 |
| 30639670 | Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. | Nanomedicine | 2019 |